ATE392216T1 - Mycobakterieller impfstoff - Google Patents

Mycobakterieller impfstoff

Info

Publication number: ATE392216T1
Authority: AT; Austria
Prior art keywords: compositions; methods; mycobacterial vaccine; subject; mycobacterial
Prior art date: 2001-11-14

Application number

AT02802568T

Other languages

English (en)

Inventor

Craig Wright

Joan Brisker

Mark Chambers

Original Assignee

Novavax Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-14

Filing date

2002-11-13

Publication date

2008-05-15

2002-11-13 Application filed by Novavax Inc filed Critical Novavax Inc

2008-05-15 Application granted granted Critical

2008-05-15 Publication of ATE392216T1 publication Critical patent/ATE392216T1/de

Links

229960005486 vaccine Drugs 0.000 title 1
239000000203 mixture Substances 0.000 abstract 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract 2
206010062207 Mycobacterial infection Diseases 0.000 abstract 1
241000186359 Mycobacterium Species 0.000 abstract 1
241000186366 Mycobacterium bovis Species 0.000 abstract 1
239000002671 adjuvant Substances 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
230000036039 immunity Effects 0.000 abstract 1
208000027531 mycobacterial infectious disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

AT02802568T 2001-11-14 2002-11-13 Mycobakterieller impfstoff ATE392216T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US33591701P	2001-11-14	2001-11-14

Publications (1)

Publication Number	Publication Date
ATE392216T1 true ATE392216T1 (de)	2008-05-15

Family

ID=23313769

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02802568T ATE392216T1 (de)	2001-11-14	2002-11-13	Mycobakterieller impfstoff

Country Status (10)

Country	Link
US (1)	US7393541B2 (de)
EP (1)	EP1467771B1 (de)
JP (1)	JP2005538923A (de)
KR (1)	KR20040081423A (de)
CN (1)	CN1612753A (de)
AT (1)	ATE392216T1 (de)
AU (1)	AU2002364952B2 (de)
CA (1)	CA2467271A1 (de)
DE (1)	DE60226175T2 (de)
WO (1)	WO2003051288A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60226175T2 (de) *	2001-11-14	2009-07-09	Novavax, Inc.	Mycobakterieller impfstoff
US8133733B2 (en)	2003-10-24	2012-03-13	Gencia Corporation	Nonviral vectors for delivering polynucleotides to target tissues
US8507277B2 (en)	2003-10-24	2013-08-13	Gencia Corporation	Nonviral vectors for delivering polynucleotides
CA2543257C (en)	2003-10-24	2013-12-31	Gencia Corporation	Methods and compositions for delivering polynucleotides
US20090123468A1 (en)	2003-10-24	2009-05-14	Gencia Corporation	Transducible polypeptides for modifying metabolism
US8062891B2 (en)	2003-10-24	2011-11-22	Gencia Corporation	Nonviral vectors for delivering polynucleotides to plants
CU23460A1 (es) *	2004-03-18	2009-12-01	Inst Finlay Ct De Investigacio	Composiciones vacunales obtenidas a partir de streptomyces
WO2006071659A1 (en) *	2004-12-29	2006-07-06	Trustees Of Boston University	Delivery of h2 antagonists
CN100999550B (zh) *	2006-01-10	2010-10-06	中国人民解放军第三○九医院	结核分枝杆菌融合蛋白及其应用
US20100291038A1 (en) *	2006-07-06	2010-11-18	Rajesh Shah	Novel Medicinal Formulation for Inducing an Immune Response in Patients with Chronic and Recurring Infections
AU2008240181B2 (en)	2007-04-12	2014-01-09	Jason Fisher	Tuberculosis vaccine and method of using same
WO2011105520A1 (ja) *	2010-02-26	2011-09-01	国立大学法人長崎大学	抗原または薬物送達複合体
KR20130010121A (ko)	2010-03-23	2013-01-25	인트렉손 코포레이션	치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도
WO2012137072A1 (en)	2011-04-06	2012-10-11	Biovaxim Limited	Therapeutic vaccine compositions inducing tolerance to hiv for treating hiv infections in humans
US9839684B2 (en)	2011-04-06	2017-12-12	Biovaxim Limited	Pharmaceutical compositions comprising inactivated HIV viral particles and non-pathogenic lactobacilli for the induction of antigen-specific immunotolerance
KR20150127587A (ko) *	2013-03-15	2015-11-17	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	결핵의 예방 또는 치료를 위한 합성 면역원
KR101696514B1 (ko) *	2014-08-18	2017-01-24	서울대학교산학협력단	신규한 온도 민감성 마이코박테리아 균주 및 이를 포함하는 마이코박테리아 감염증에 대한 백신 조성물
US11077179B2 (en) *	2017-08-10	2021-08-03	Epicgenetics, Inc.	Method for treating fibromyalgia and chronic fatigue syndrome
WO2020115161A1 (en)	2018-12-04	2020-06-11	Sabiotec Spin-Off Sl	Immunostimulant for use against pathogens
CN115154595B (zh) *	2021-12-22	2026-02-17	国药集团动物保健股份有限公司	纳米结构脂质载体佐剂的制备方法以及兽用疫苗

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5474848A (en) *	1987-03-13	1995-12-12	Micro-Pak, Inc.	Paucilamellar lipid vesicles
US6387373B1 (en) *	1993-01-15	2002-05-14	Novavax, Inc.	Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
DE69533693T2 (de) *	1994-02-24	2005-12-22	Novavax Inc.(n.d.Ges.d.Staates Delaware)	Impfstoffe, die paucilamelläre Lipidvesikel als Adjuvans enthalten
US6290987B1 (en) *	1998-09-27	2001-09-18	Generex Pharmaceuticals, Inc.	Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
SE9900495D0 (sv) *	1999-02-12	1999-02-12	Pharmatrix Ab	Vaccine composition
WO2001070663A2 (en) *	2000-03-17	2001-09-27	Corixa Corporation	Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
GB0109297D0 (en) *	2001-04-12	2001-05-30	Glaxosmithkline Biolog Sa	Vaccine
DE60226175T2 (de) *	2001-11-14	2009-07-09	Novavax, Inc.	Mycobakterieller impfstoff
US20050175630A1 (en) *	2003-12-23	2005-08-11	Eyal Raz	Immunogenic compositions and methods of use thereof

2002
- 2002-11-13 DE DE60226175T patent/DE60226175T2/de not_active Expired - Lifetime
- 2002-11-13 JP JP2003552221A patent/JP2005538923A/ja not_active Withdrawn
- 2002-11-13 KR KR10-2004-7007377A patent/KR20040081423A/ko not_active Ceased
- 2002-11-13 CA CA002467271A patent/CA2467271A1/en not_active Abandoned
- 2002-11-13 CN CNA02826665XA patent/CN1612753A/zh active Pending
- 2002-11-13 EP EP02802568A patent/EP1467771B1/de not_active Expired - Lifetime
- 2002-11-13 WO PCT/US2002/036336 patent/WO2003051288A2/en not_active Ceased
- 2002-11-13 AU AU2002364952A patent/AU2002364952B2/en not_active Ceased
- 2002-11-13 AT AT02802568T patent/ATE392216T1/de not_active IP Right Cessation
2004
- 2004-05-13 US US10/846,939 patent/US7393541B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2005538923A (ja)	2005-12-22
US7393541B2 (en)	2008-07-01
DE60226175D1 (de)	2008-05-29
KR20040081423A (ko)	2004-09-21
WO2003051288A3 (en)	2003-11-27
EP1467771B1 (de)	2008-04-16
AU2002364952A1 (en)	2003-06-30
US20050118201A1 (en)	2005-06-02
DE60226175T2 (de)	2009-07-09
CN1612753A (zh)	2005-05-04
EP1467771A4 (de)	2006-01-11
CA2467271A1 (en)	2003-06-26
EP1467771A2 (de)	2004-10-20
WO2003051288A2 (en)	2003-06-26
AU2002364952B2 (en)	2008-04-10

Legal Events

Date	Code	Title	Description
2008-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60226175D1 (de)	2008-05-29	Mycobakterieller impfstoff
DE602004020189D1 (de)	2009-05-07	Adjuvante influenza-vakzine
DK1401489T4 (da)	2013-07-01	Solubilisering af kapselpolysaccharid
DK1104306T3 (da)	2006-05-22	Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
WO2003080114A3 (en)	2003-11-06	Imidazoquinoline adjuvants for vaccines
CY1106669T1 (el)	2012-05-23	Βελτιωμενο i mycoplasma hy opneumoniae/ i εμβολιο βακτηρινης
CY1115842T1 (el)	2017-01-25	Συμπληρωμενο ομv εμβολιο κατα μηνιγγιtiδοκοκκου
PT865297E (pt)	2003-03-31	Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
WO2004030608A3 (en)	2005-03-10	Nanoemulsion vaccines
GB2386072A (en)	2003-09-10	Novel vaccine
NO20063254L (no)	2006-07-13	Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist
CY1108526T1 (el)	2014-04-09	Εμβολια εναντι καρκινων
WO2002010343A3 (en)	2002-10-10	Temperature-sensitive live vaccine for mycoplasma hyopneumoniae
DK1395283T3 (da)	2007-07-09	Heterolog beskyttelse induceret ved immunisering med Invaplex-vaccine
WO2000050073A3 (en)	2001-02-22	Caulobacter lps immunoadjuvant
SG147465A1 (en)	2008-11-28	Vaccine
WO2006095176A3 (en)	2007-04-05	Vaccine formulation
MXPA05009447A (es)	2005-11-23	Vacunas bovinas con adyuvante.
ATE353226T1 (de)	2007-02-15	Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
UA67251A (en)	2004-06-15	Strain paramixovirus-3 bovis "zksm" for the preparation of vaccines and diagnosticums